Type 2 Diabetes

A cross-sectional analysis of NHANES data paints a grim picture related to rates of patients with diabetes achieving goals for glycemic, blood pressure, and lipid control.

A systematic review of clinical trials notes that topical eye drops may lead to favorable retinal and visual outcomes, despite heterogeneity across multiple studies.

An expert discussion on the recent FDA committee decision to support teplizumab in delaying clinical type 1 diabetes.

An analysis of data from nearly 500k patients suggests patients with diabetes experiencing frequent insomnia were at an 87% increased risk of all-cause mortality compared to those with neither sleep disturbances nor diabetes.

Thought leaders in diabetes provide closing remarks about the importance of continuous awareness of glycemic control in patients as well as the need for effective communication between patients and providers. 

A panel of experts in the treatment of diabetes discusses the importance of self-management of blood glucose levels and emphasizes the need for multidisciplinary care teams and referrals for optimal disease management.

Thought leaders in diabetes discuss challenges of insurance coverage for new formulations of glucagon and comment on the potential for long-term cost savings due to decreased overall healthcare system utilization.

Experts in endocrinology build a discussion on new intranasal and injectable formulations of glucagon and discuss their benefits compared to glucagon kits that require reconstitution.

Key thought leaders in endocrinology review different signs and symptoms of hypoglycemia across vulnerable patient populations and discuss factors that may impact the pharmacologic management of blood glucose levels.

A panel of thought leaders in the management of diabetes reviews the mainstays of treatment for hypoglycemic episodes and builds a discussion on effective non-pharmacologic strategies for raising blood glucose levels.

Key opinion leaders in diabetes comment on various blood glucose tests to assess hypoglycemia and prevent future episodes.

A multidisciplinary panel of experts shares insights into identifying symptoms of hypoglycemia and highlights the importance of stratifying level 1, 2, and 3 blood glucose levels when making the differential diagnosis in diabetes.

Expert panelists provide an overview of health complications associated with mild and severe hypoglycemic episodes and emphasize the importance of patient awareness and early recognition to improve quality of life and health-related outcomes.

A panel of experts in diabetes builds a discussion on hypoglycemia and shares key insights into its impact on community health by considering overall challenges of glucose management.

A panel of experts in diabetes builds a discussion on hypoglycemia and shares key insights into its impact on community health by considering overall challenges of glucose management.

Our latest case report from Dr. Brady Pregerson features a man in his 30s presenting to the ED after drinking and admits to forgetting his insulin and poor adherence to other antidiabetes medication. Can you determine the correct diagnosis?

An analysis of food frequency questionnaire and biomarker data from more than 7000 adults indicates consumption of 2 or more servings of whole fruit per day was associated with 36% lower odds of developing diabetes in the next half-decade.

The FDA has announced the approval of semaglutide 2.4 mg (Wegovy) for chronic weight management in patients with obesity or overweight—the first drug to receive such an approval from the FDA in more than half a decade.

The indication makes the Novo Nordisk product the first weekly injection GLP-1 agonist approved for managing overweight and obesity.

A look at more than 2800 older patients with type 1 diabetes indicates experiencing severe glycemic events was linked to an increased risk of developing dementia.

A retrospective look at patients who initated real-time CGM versus noninitiators indicates CGM use resulted in significant reductions in HbA1c and also reduced the number of outpatient and telephone visits among patients with type 1 diabetes and type 2 diabetes.

A trial of more than 150 patients with type 2 diabetes using basal insulin without prandial insulin suggests CGM use among these patients could lower HbA1c and improve time in target range compared to traditional blood glucose monitoring.

Analysis of claims data from the Symphony database offers clinicians greater insight into the impact of diabetes, both type 1 and type 2, on thyroid eye disease in US patients.

A systematic review and meta-analysis presented at AACE 2021 shed light on risk factors associated with increased odds of developing peripheral artery disease among patients with type 2 diabetes.

A systematic review and meta-analysis presented at AACE 2021 sheds light on risk factors associated with increased odds of developing peripheral artery disease among patients with type 2 diabetes.